NASDAQ:EMBC Embecta (EMBC) Stock Price, News & Analysis $15.31 +0.18 (+1.19%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$15.02▼$15.7250-Day Range$11.46▼$16.4652-Week Range$9.93▼$19.79Volume395,791 shsAverage Volume420,816 shsMarket Capitalization$882.93 millionP/E Ratio12.65Dividend Yield3.92%Price Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Embecta alerts: Email Address Embecta MarketRank™ Stock AnalysisAnalyst RatingReduce1.50 Rating ScoreUpside/Downside21.6% Downside$12.00 Price TargetShort InterestHealthy3.70% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainabilityN/ANews Sentiment0.37Based on 6 Articles This WeekInsider TradingN/AProj. Earnings Growth-6.17%From $2.43 to $2.28 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.59 out of 5 starsMedical Sector629th out of 910 stocksSurgical & Medical Instruments Industry74th out of 95 stocks 0.8 Analyst's Opinion Consensus RatingEmbecta has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageEmbecta has only been the subject of 1 research reports in the past 90 days.Read more about Embecta's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.70% of the float of Embecta has been sold short.Short Interest Ratio / Days to CoverEmbecta has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Embecta has recently decreased by 14.16%, indicating that investor sentiment is improving significantly. Previous Next 3.3 Dividend Strength Dividend LeadershipEmbecta is a leading dividend payer. It pays a dividend yield of 3.65%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthEmbecta does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Embecta is 49.59%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Embecta will have a dividend payout ratio of 26.32% next year. This indicates that Embecta will be able to sustain or increase its dividend.Read more about Embecta's dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EMBC. Previous Next 3.0 News and Social Media Coverage News SentimentEmbecta has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Embecta this week, compared to 2 articles on an average week.Search Interest3 people have searched for EMBC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added Embecta to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Embecta insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.28% of the stock of Embecta is held by insiders.Percentage Held by Institutions93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Embecta's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Embecta are expected to decrease by -6.17% in the coming year, from $2.43 to $2.28 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Embecta is 12.65, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.87.Price to Earnings Ratio vs. SectorThe P/E ratio of Embecta is 12.65, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.64.Read more about Embecta's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Embecta Stock (NASDAQ:EMBC)Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.Read More EMBC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EMBC Stock News HeadlinesSeptember 4 at 10:43 PM | markets.businessinsider.comBTIG Reaffirms Their Hold Rating on Embecta Corporation (EMBC)September 4 at 10:43 PM | markets.businessinsider.comRecommendation to Sell: Anticipated Costs and Competition Challenge Embecta’s New Pump ProgramSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 3, 2024 | markets.businessinsider.comEmbecta Corp. Announces FDA Clearance Of Its Disposable Insulin Delivery SystemSeptember 3, 2024 | globenewswire.comembecta Announces FDA Clearance of its Disposable Patch Pump for Insulin Delivery Informed by the Unique Needs of People with Type 2 DiabetesAugust 22, 2024 | globenewswire.comembecta to Participate in Investor EventsAugust 19, 2024 | lse.co.ukEmbecta Corp Share Price (EMBC.US)August 17, 2024 | ca.finance.yahoo.comHQY Dec 2024 80.000 putSeptember 7, 2024 | Porter & Company (Ad)Why billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. August 17, 2024 | ca.finance.yahoo.comHQY Sep 2024 95.000 callAugust 16, 2024 | finance.yahoo.comEmbecta (NASDAQ:EMBC) Is Posting Promising Earnings But The Good News Doesn’t Stop ThereAugust 15, 2024 | finance.yahoo.comEmbecta (NASDAQ:EMBC) Is Due To Pay A Dividend Of $0.15August 13, 2024 | msn.comEmbecta Corp. (EMBC) Just Overtook the 200-Day Moving AverageAugust 13, 2024 | msn.comEmbecta Corp. (EMBC) Recently Broke Out Above the 20-Day Moving AverageAugust 12, 2024 | finance.yahoo.comEmbecta Third Quarter 2024 Earnings: Beats ExpectationsAugust 10, 2024 | insidermonkey.comEmbecta Corp. (NASDAQ:EMBC) Q3 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comEmbecta Corp. (EMBC) Q3 2024 Earnings Call TranscriptAugust 9, 2024 | investorplace.comEMBC Stock Earnings: Embecta Beats EPS, Beats Revenue for Q3 2024See More Headlines Receive EMBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Embecta and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 6/14 Dividend5/24/2024Dividend Payable6/14/2024Last Earnings8/09/2024Ex-Dividend for 9/13 Dividend8/27/2024Today9/07/2024Dividend Payable9/13/2024Fiscal Year End9/30/2024Next Earnings (Estimated)11/19/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:EMBC CUSIPN/A CIK1872789 Webwww.embecta.com Phone201-847-6880FaxN/AEmployees2,200Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside-21.6%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$1.21 Trailing P/E Ratio12.65 Forward P/E Ratio6.30 P/E GrowthN/ANet Income$70.40 million Net Margins6.23% Pretax Margin5.02% Return on Equity-19.09% Return on Assets12.27% Debt Debt-to-Equity RatioN/A Current Ratio2.11 Quick Ratio1.61 Sales & Book Value Annual Sales$1.12 billion Price / Sales0.79 Cash Flow$3.46 per share Price / Cash Flow4.43 Book Value($13.23) per share Price / Book-1.16Miscellaneous Outstanding Shares57,670,000Free Float57,509,000Market Cap$882.93 million OptionableOptionable Beta1.00 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Devdatt Kurdikar (Age 56)President, CEO & Director Comp: $2.2MMr. Jacob P. Elguicze (Age 51)Senior VP & CFO Comp: $1.05MMr. Brian R. Capone (Age 49)VP, Chief Accounting Officer & Corporate Controller Comp: $645.16kMr. Jeffrey Z. Mann (Age 52)Senior VP, General Counsel, Head of Business Development & Corporate Secretary Comp: $959.45kMr. Shaun Curtis (Age 55)Senior Vice President of Global Manufacturing & Supply Chain Comp: $915.67kMs. Colleen Riley (Age 60)Senior VP & Chief Technology Officer Mr. Pravesh KhandelwalVP & Head of Investor RelationsMs. Ginny BlockiSenior Vice President of Global Marketing & Product ManagementMs. Jean M. Casner (Age 66)Senior VP & Chief Human Resources Officer Mr. Tom Blount (Age 50)Senior VP & President of North America More ExecutivesKey CompetitorsAxonicsNASDAQ:AXNXEnvistaNYSE:NVSTTandem Diabetes CareNASDAQ:TNDMInari MedicalNASDAQ:NARILivaNovaNASDAQ:LIVNView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Sold 367,975 shares on 8/19/2024Ownership: 0.020%Algert Global LLCBought 113,633 shares on 8/16/2024Ownership: 0.267%Creative PlanningBought 36,302 shares on 8/16/2024Ownership: 0.063%Mackenzie Financial CorpBought 13,225 shares on 8/15/2024Ownership: 0.080%The Manufacturers Life Insurance Company Bought 1,025 shares on 8/15/2024Ownership: 0.039%View All Insider TransactionsView All Institutional Transactions EMBC Stock Analysis - Frequently Asked Questions How have EMBC shares performed this year? Embecta's stock was trading at $18.93 at the start of the year. Since then, EMBC stock has decreased by 19.1% and is now trading at $15.31. View the best growth stocks for 2024 here. How were Embecta's earnings last quarter? Embecta Corp. (NASDAQ:EMBC) released its quarterly earnings data on Friday, August, 9th. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.46 by $0.28. The firm's revenue for the quarter was down 4.8% compared to the same quarter last year. Who are Embecta's major shareholders? Top institutional investors of Embecta include American Century Companies Inc. (5.48%), Yacktman Asset Management LP (4.88%), Bank of New York Mellon Corp (1.38%) and AQR Capital Management LLC (1.07%). Insiders that own company stock include Devdatt Kurdikar, Jacob Elguicze, Jeffrey Z Mann and David F Melcher. View institutional ownership trends. How do I buy shares of Embecta? Shares of EMBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EMBC) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Embecta Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Embecta With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
